{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:43:12Z","timestamp":1790602992398,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejves.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Vascular and Endovascular Surgery"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejvs.2021.09.031","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T08:01:27Z","timestamp":1636704087000},"page":"981-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Roman N.","family":"Rodionov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-8410","authenticated-orcid":false,"given":"Frederik","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-9139","authenticated-orcid":false,"given":"Helmut","family":"L\u2019Hoest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-2942","authenticated-orcid":false,"given":"Natalia","family":"Jarzebska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-3319","authenticated-orcid":false,"given":"Christian-Alexander","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejvs.2021.09.031_bib1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejvs.2021.09.031_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejvs.2021.09.031_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejvs.2021.09.031_bib4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejvs.2021.09.031_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejvs.2021.09.031_bib6","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejvs.2021.09.031_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLos One"},{"key":"10.1016\/j.ejvs.2021.09.031_bib8","doi-asserted-by":"crossref","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","article-title":"Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials","volume":"163","author":"Miyashita","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejvs.2021.09.031_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40618-019-01103-9","article-title":"Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis","volume":"43","author":"Dorsey-Trevino","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ejvs.2021.09.031_bib10","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejvs.2021.09.031_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejvs.2021.09.031_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2021.09.031_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cpcardiol.2018.06.004","article-title":"SGLT-2 inhibitors and peripheral artery disease: a statistical hoax or reality?","volume":"44","author":"Chatterjee","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ejvs.2021.09.031_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejvs.2020.11.013","article-title":"Editor's Choice \u2013 The GermanVasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease","volume":"61","author":"Kreutzburg","year":"2021","journal-title":"Eur J Vasc Endovasc"},{"key":"10.1016\/j.ejvs.2021.09.031_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejvs.2019.08.006","article-title":"Editor's Choice \u2013 Comorbidity patterns among patients with peripheral arterial occlusive disease in Germany: a trend analysis of health insurance claims data","volume":"59","author":"Kreutzburg","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2021.09.031_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2021.09.031_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013\u20132018","volume":"43","author":"Dave","year":"2020","journal-title":"Diab Care"},{"key":"10.1016\/j.ejvs.2021.09.031_bib18","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ejvs.2021.09.031_bib19","article-title":"Long-term effectiveness and safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease","volume":"9","author":"Peters","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ejvs.2021.09.031_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00772-020-00679-4","article-title":"Quality of care in surgical\/interventional vascular medicine: what can routinely collected data from the insurance companies achieve?","volume":"25","author":"Peters","year":"2020","journal-title":"Gef\u00e4sschirurgie"},{"key":"10.1016\/j.ejvs.2021.09.031_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","article-title":"Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence","volume":"36","author":"Reinecke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2021.09.031_bib22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ejvs.2021.09.031_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A\u00a0modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.ejvs.2021.09.031_bib24","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.ejvs.2021.09.031_bib25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/CIRCULATIONAHA.117.032799","article-title":"Reduced mortality with sodium-glucose cotransporter-2 inhibitors in observational studies: avoiding immortal time bias","volume":"137","author":"Suissa","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2021.09.031_bib26","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejvs.2021.09.031_bib27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/pds.5206","article-title":"Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data","volume":"30","author":"Yang","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejvs.2021.09.031_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","article-title":"Does lower limb amputation concern all SGLT2 inhibitors?","volume":"14","author":"Scheen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejvs.2021.09.031_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1574886315666200805103053","article-title":"use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation","volume":"16","author":"Werkman","year":"2021","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.ejvs.2021.09.031_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1534734619878090","article-title":"Canagliflozin and amputation risk: evidence so far","volume":"19","author":"Papadokostaki","year":"2020","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.ejvs.2021.09.031_bib31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers","volume":"21","author":"Yang","year":"2019","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.ejvs.2021.09.031_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diab Obes Metab"}],"container-title":["European Journal of Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107858842100770X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107858842100770X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:57:26Z","timestamp":1761047846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107858842100770X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S107858842100770X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejvs.2021.09.031","relation":{},"ISSN":["1078-5884"],"issn-type":[{"value":"1078-5884","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Vascular and Endovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejvs.2021.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Vascular Surgery. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}